Study designs
¹A multicenter, open-label, prospective study was undertaken in MMF-treated renal transplant patients including patients experiencing GI complaints were converted to equimolar EC-MPS (Cohort A, n=177) and patients without GI complaints remained on MMF (Cohort B, n=101), to determine if patients with GI complaints who are converted from MMF to EC-MPS experience improvements in GI symptom severity and HRQoL; and to evaluate the impact of GI symptoms on patients’ perceptions of symptom severity, GI-specific HRQoL, and general HRQoL.

²A retrospective study comparing MMF and EC-MPS in all consecutive kidney transplants (n=1,709) between 2000 and 2006 was conducted to determine whether there was a clinically significant difference in dose alterations and outcomes with EC-MPS compared with MMF.

³The present randomized, multicenter, open-labeled, 12-week study included renal transplant recipients experiencing GI adverse events due to MMF treatment. Patients were randomized to continue with MMF (n=54) or change to EC-MPS (n=59). Patients were converted at equimolar doses, and dose was optimized between weeks 2 and 6 to achieve maximum tolerated dose.

Abbreviations:
GI: gastrointestinal; MMF: mycophenolate mofetil; MPA: mycophenolic acid; BPAR: biopsy-proven acute rejection

References:
1. Chan L, et al. Transplantation. 2006;81(9):1290-1297. 2. Sollinger HW, et al. Transplantation. 2010;89(4):446-451. 3. Ortega F, et al. Transplatation. 2011;92:426-432.